A colon-targeted arabinoxylan hydrogel and preparation method thereof

Through pentosanase enzymatic and cross-linking reaction of peroxidase and glucose oxidase, arabinoxic hydrogel with high cross-linking strength was prepared, which solved the swelling rate of polysaccharide hydrogels in the stomach and small intestine. The problem of high and low degradation rates in the colon achieves high drug loading and good colon targeting performance.

CN115490883BActive Publication Date: 2024-11-29ANHUI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202211012431.0
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-08-23
Publication Date
2024-11-29
Estimated Expiration
2042-08-23

AI Technical Summary

Technical Problem

The existing polysaccharide flora triggered colon-targeted hydrogels have high swelling rate in the stomach and small intestine and low degradation rate in the colon, resulting in early release of drugs, and insufficient drug loading and release rates, which limits them. Promotion of clinical applications.

Method used

Using water-soluble arabinoxilan as raw material, hydrogels with high crosslinking strength are prepared by enzymatic pentosanase and crosslinking reactions of peroxidase and glucose oxidase to form a porous structure to improve the drug package. The load rate is stable in the stomach and small intestine environment until the colon is reduced by microorganisms to release drugs.

Benefits of technology

It significantly improves the drug loading and drug release rate of the hydrogel, achieves good colon targeting performance, reduces drug release in the gastric and small intestinal environment, and enhances the therapeutic effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0003811442220000111
    Figure BDA0003811442220000111
  • Figure BDA0003811442220000121
    Figure BDA0003811442220000121
Patent Text Reader

Abstract

The invention discloses a colon-targeted arabinoxylan hydrogel and a preparation method thereof, comprising the following steps: dissolving water-soluble arabinoxylan in water to obtain an arabinoxylan solution, then adding pentosanase, performing enzymolysis reaction, inactivating the enzyme in a boiling water bath after the reaction is completed, sequentially adding glucose, peroxidase and glucose oxidase after cooling, stirring at room temperature for cross-linking reaction, and obtaining a colon-targeted arabinoxylan hydrogel. The hydrogel of the invention has good colon-targeting performance, high drug loading and high drug release rate, and has good application potential as an oral colon-targeted drug carrier.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of functional hydrogel materials, and in particular to a colon-targeted arabinoxylan hydrogel and a preparation method thereof. Background Art

[0002] Oral administration of functional ingredients and drugs is the preferred way to achieve their efficacy. As a fourth-generation drug preparation, the oral colon-specific drug delivery system (OCDDS) mainly uses pharmaceutical methods such as drug modification and coating to protect drugs or functional ingredients from protease degradation and pH in the gastrointestinal tract and inactivation. It uses the characteristics of the colon with relatively high pH (pH>8), low concentration and low activity of proteolytic enzymes, long drug residence time, and low penetration resistance of the colon wall to large molecules, which is conducive to full absorption, thereby enhancing the therapeutic effect and reducing drug usage and toxic side effects.

[0003] According to different release mechanisms, colon-targeted systems mainly include pH-dependent, time-dependent, pressure-controlled, and flora-triggered types. Due to differences in gastrointestinal transit time, upper gastrointestinal pH, and health status among individuals, pH-dependent, time-dependent, and pressure-controlled colon-targeted systems may lead to premature or inaccurate release of nutrients. The flora-triggered OCDDS uses enzymes produced by intestinal flora to act on the packaging material to cause drug release. It is less affected by diet, disease, individual differences, etc., and is more targeted. It has been a research hotspot for OCDDS in recent years.

[0004] At present, there are more than a dozen targeted positioning materials that have been developed and synthesized. Among them, polysaccharide macromolecules as flora-triggered OCDDS have received widespread attention and have been included in the pharmacopoeias of various countries because of their safety and good biocompatibility. However, polysaccharides still have defects such as few types, poor formability, strong water solubility and swelling, which can easily lead to premature drug release. In order to achieve its efficacy as a colon-targeted drug carrier, the hydrogel must not only have a low swelling rate in the stomach and small intestine, a high degradation rate in the colon, but also have a good drug loading and drug release rate. Limited by the above factors, most of the research on colon-targeted hydrogels is still in the theoretical research stage, and colon-targeted preparations based on polysaccharides and their derivatives are rarely produced and marketed. Therefore, it is of great significance to develop and utilize new polysaccharide flora-triggered colon-targeted materials. Summary of the invention

[0005] Based on the technical problems existing in the background technology, the present invention proposes a colon-targeted arabinoxylan hydrogel and a preparation method thereof.

[0006] The invention provides a method for preparing a colon-targeted arabinoxylan hydrogel, comprising the following steps: dissolving water-soluble arabinoxylan in water to obtain an arabinoxylan aqueous solution with a concentration of 8-20wt%, then adding pentosanase, performing enzymolysis reaction at 20-30 DEG C for 2-5min, inactivating the enzyme in a boiling water bath after the reaction, sequentially adding glucose, peroxidase and glucose oxidase after cooling, stirring at room temperature for cross-linking reaction, and obtaining a colon-targeted arabinoxylan hydrogel; wherein, based on the mass of the arabinoxylan, the amount of the pentosanase used is 40-80μg / g of the arabinoxylan.

[0007] Preferably, the water-soluble arabinoxylan is prepared from wheat flour by using an enzymatic hydrolysis-water extraction-alcohol precipitation method.

[0008] Preferably, the preparation method of the water-soluble arabinoxylan is as follows: wheat flour and water are mixed evenly, stirred at room temperature for a period of time, centrifuged, the supernatant is taken, concentrated, high-temperature α-amylase is added for enzymatic hydrolysis reaction, and then glucosidase is added for enzymatic hydrolysis reaction, then cooled and centrifuged, the obtained supernatant is precipitated with ethanol to obtain a precipitate, the precipitate is redissolved in water, centrifuged, the supernatant is taken, and ethanol is precipitated again, the obtained precipitate is washed with anhydrous ethanol, and then freeze-dried to obtain the water-soluble arabinoxylan.

[0009] Preferably, in the method for preparing the water-soluble arabinoxylan, high temperature α-amylase is added for enzymatic hydrolysis for 1-2 hours.

[0010] Preferably, in the method for preparing the water-soluble arabinoxylan, glucosidase is added for enzymatic hydrolysis for 1-2 hours.

[0011] Preferably, in the preparation method of the water-soluble arabinoxylan, based on the mass of wheat flour, the amount of high-temperature α-amylase is 0.3-0.5 kg / t wheat flour, and the temperature of the high-temperature α-amylase enzymolysis reaction is 80-95° C. The amount of glucosidase is 1-2 L / t wheat flour, and the temperature of the glucosidase enzymolysis reaction is 55-70° C.

[0012] Preferably, in the preparation method of the water-soluble arabinoxylan, the mass ratio of wheat flour to water is 1:(5-10), stirring is carried out at room temperature for 40-60 minutes, and the supernatant is concentrated to 1 / 4-1 / 8 of the original volume at a concentration temperature of 40-65°C.

[0013] Preferably, in the method for preparing the water-soluble arabinoxylan, the ethanol concentration used for alcohol precipitation is 60-70%, and the alcohol precipitation further comprises standing at 4-10° C. for 18-36 hours to obtain a precipitate.

[0014] Preferably, based on the mass of arabinoxylan, the amount of glucose is 0.033-0.33 mg / g arabinoxylan, the amount of peroxidase is 4.8-6.0 U / g arabinoxylan, and the amount of glucose oxidase is 2000-60000 μg / g arabinoxylan.

[0015] Preferably, the cross-linking reaction time is 5-60 min.

[0016] The invention also provides a colon-targeted arabinoxylan hydrogel, which is prepared by the preparation method.

[0017] The present invention also provides an application of the arabinoxylan hydrogel as a colon-targeted drug carrier.

[0018] The present invention also provides an oral colon-targeted drug preparation, which comprises an active drug and a drug carrier for encapsulating the active drug, wherein the drug carrier is a colon-targeted arabinoxylan hydrogel prepared by the preparation method;

[0019] Alternatively, the pharmaceutical preparation is prepared by replacing the water in the preparation method with a buffer solution containing an active drug.

[0020] The present invention also provides an oral colon-targeted drug preparation, the preparation method of which comprises the following steps:

[0021] The water-soluble arabinoxylan is dissolved in a buffer solution containing an active drug to obtain an arabinoxylan solution containing the active drug, and then pentosanase is added to perform an enzymolysis reaction at 20-30°C for 2-5 minutes. After the reaction, the enzyme is inactivated in a boiling water bath, and glucose, peroxidase and glucose oxidase are added in sequence after cooling. The mixture is stirred at room temperature for cross-linking reaction to obtain an oral colon-targeted drug preparation. In the arabinoxylan solution containing the active drug, the mass concentration of the arabinoxylan is 8-20wt%; based on the mass of the arabinoxylan, the amount of the pentosanase is 40-80μg / g of the arabinoxylan.

[0022] The buffer solution is preferably a phosphate buffered saline (PBS).

[0023] Preferably, the amount of glucose used is 0.033-0.33 mg / g arabinoxylan, the amount of peroxidase used is 4.8-6.0 PU / g arabinoxylan, and the amount of glucose oxidase used is 2000-60000 μg / g arabinoxylan.

[0024] Preferably, the cross-linking reaction time is 5-60 min.

[0025] Preferably, the mass ratio of the active drug to arabinoxylan is 1:(4-10).

[0026] Preferably, the active drug is a polyphenol, a polypeptide or a protein drug.

[0027] Arabinoxylan (AX) is a non-starch polysaccharide found in cereals, accounting for about 80-90% of the total amount of cereal bran, and is cheap and easy to obtain. Its basic structure is a β-D-pyranose main chain and an α-L-arabinofuranosyl side chain connected by 1,4-glycosidic bonds. At the C5 position of some arabinose, there is ferulic acid (FA) connected by an ester bond, and this arabinose is usually connected to the C3 position of xylose. Studies have shown that AX is not a simple "inert" fiber matrix. AX cannot be used by the human gastrointestinal tract, but can be specifically degraded by colon bacteria, and has good intestinal prebiotic effects. At the same time, when the AX solution coexists with some oxidants, FA forms intermolecular cross-links to generate ferulic acid diploid or triploid, thereby forming a high-viscosity solution, and even cross-linking to form a gel.

[0028] Glucose oxidase is an important industrial enzyme in the food industry, widely used in deoxygenation of foods such as wine, beer, juice, and milk powder, flour improvement, and prevention of food browning. Glucose oxidase (GOX) covalently cross-linked AX gel formation conditions are mild, non-toxic, and have good biocompatibility. It is insensitive to changes in pH and electrolyte concentration, cannot be digested by gastric juice, and can be decomposed by intestinal microorganisms to exert its intestinal probiotic effects.

[0029] The beneficial effects of the present invention are:

[0030] The invention uses water-soluble arabinoxylan as a raw material, firstly adds an appropriate amount of pentosanase into an arabinoxylan aqueous solution of appropriate concentration for enzymatic hydrolysis treatment, so that the chain segments of the arabinoxylan are partially degraded, and then the ferulic acid on the chain segments is moderately cross-linked under the action of peroxidase and glucose oxidase to form a hydrogel with high cross-linking strength, wherein, since the partially degraded arabinoxylan chain segments treated with an appropriate amount of pentosanase can form a more uniform and highly porous honeycomb structure in microscopic terms after moderate cross-linking, the drug encapsulation rate of the cross-linked hydrogel can be significantly improved, and the more dense grid structure can also reduce the release of drugs in the stomach and small intestine environment, and the moderate degradation of the arabinoxylan chain segments is conducive to improving the drug release rate of the hydrogel in the colon; at the same time, the hydrogel can maintain its cross-linking structure in the stomach and small intestine environment, and the swelling rate is extremely low, and is degraded by enzymes produced by microorganisms in the colon, the spatial network structure of the hydrogel is destroyed, the drug is released, and the hydrogel has good colon targeting performance. The hydrogel of the invention has good colon targeting performance, high drug loading and high drug release rate, and has good application potential as an oral colon targeting drug carrier. DETAILED DESCRIPTION

[0031] The technical solution of the present invention is described in detail below through specific embodiments.

[0032] In the following examples and comparative examples, the preparation method of water-soluble arabinoxylan is:

[0033] The wheat flour and water were mixed evenly at a mass ratio of 1:5, stirred at room temperature for 40 minutes, centrifuged at 4000 rpm for 10 minutes, the supernatant was taken, concentrated to 1 / 4 of the original volume by rotary evaporation at 60°C, and then high-temperature α-amylase was added, and enzymatic hydrolysis reaction was carried out at 85°C for 2 hours, and then glucosidase was added, and enzymatic hydrolysis reaction was carried out at 60°C for 2 hours, and then cooled, centrifuged at 4000 rpm for 20 minutes, and the obtained supernatant was precipitated with 65% ethanol. The mixture was allowed to stand at 4°C for 20 hours to obtain a precipitate, which was redissolved in water and centrifuged at 2000 rpm for 10 minutes. The supernatant was taken and precipitated with 65% ethanol. The mixture was allowed to stand at 4°C for 20 hours, and the precipitate was washed with anhydrous ethanol and then freeze-dried to obtain the product. Based on the mass of wheat flour, the dosage of high-temperature α-amylase was 0.4 kg / t wheat flour, and the dosage of glucosidase was 1.2 L / t wheat flour. High-temperature α-amylase: BAN 480 L, 480 KNU / g, Novozymes Biotech Co., Ltd., glucosidase: AMG 300 L, 300 AGU / g, Novozymes Biotech Co., Ltd.

[0034] Pentosanase: 2500FXU(W) / g, Novozymes Biotech Ltd.

[0035] Peroxidase: 240U / g, Sigma, USA.

[0036] Glucose oxidase: 10000GODU / g, Novozymes Biotech Ltd.

[0037] Example 1

[0038] A method for preparing a colon-targeted arabinoxylan hydrogel comprises the following steps: dissolving water-soluble arabinoxylan in water to obtain an arabinoxylan aqueous solution with a concentration of 8wt%, then adding pentosanase, performing enzymolysis reaction at 20 DEG C for 5 minutes, inactivating the enzyme in a boiling water bath after the reaction, sequentially adding glucose, peroxidase and glucose oxidase after cooling, stirring at room temperature for cross-linking reaction for 60 minutes, and obtaining a colon-targeted arabinoxylan hydrogel; wherein, based on the mass of arabinoxylan, the amount of pentosanase is 40μg / g arabinoxylan, the amount of glucose is 0.033mg / g arabinoxylan, the amount of peroxidase is 4.8PU / g arabinoxylan, and the amount of glucose oxidase is 2000μg / g arabinoxylan.

[0039] Example 2

[0040] A method for preparing a colon-targeted arabinoxylan hydrogel comprises the following steps: dissolving water-soluble arabinoxylan in water to obtain an arabinoxylan aqueous solution with a concentration of 20wt%, then adding pentosanase, performing enzymolysis reaction at 30 DEG C for 2min, inactivating the enzyme in a boiling water bath after the reaction, sequentially adding glucose, peroxidase and glucose oxidase after cooling, stirring at room temperature for cross-linking reaction for 5min, and obtaining a colon-targeted arabinoxylan hydrogel; wherein, based on the mass of arabinoxylan, the amount of pentosanase is 80μg / g arabinoxylan, the amount of glucose is 0.33mg / g arabinoxylan, the amount of peroxidase is 6.0PU / g arabinoxylan, and the amount of glucose oxidase is 60000μg / g arabinoxylan.

[0041] Example 3

[0042] A method for preparing a colon-targeted arabinoxylan hydrogel comprises the following steps: dissolving water-soluble arabinoxylan in water to obtain an arabinoxylan aqueous solution with a concentration of 10 wt%, then adding pentosanase, performing enzymolysis reaction at 25 DEG C for 3 minutes, inactivating the enzyme in a boiling water bath after the reaction, sequentially adding glucose, peroxidase and glucose oxidase after cooling, stirring at room temperature for cross-linking reaction for 20 minutes, and obtaining a colon-targeted arabinoxylan hydrogel; wherein, based on the mass of arabinoxylan, the amount of pentosanase is 50 μg / g arabinoxylan, the amount of glucose is 0.2 mg / g arabinoxylan, the amount of peroxidase is 5.5 PU / g arabinoxylan, and the amount of glucose oxidase is 5000 μg / g arabinoxylan.

[0043] Example 4

[0044] The invention discloses a method for preparing an oral colon-targeted drug preparation, comprising the following steps: dissolving water-soluble arabinoxylan in a phosphate buffer solution (0.01M, pH=6.0) containing ferulic acid to obtain an arabinoxylan solution containing ferulic acid (wherein the concentration of arabinoxylan is 10wt%), then adding pentosanase, performing enzymolysis reaction at 25°C for 3min, inactivating the enzyme in a boiling water bath after the reaction, sequentially adding glucose, peroxidase and glucose oxidase after cooling, stirring at room temperature for cross-linking reaction for 20min, and obtaining an oral colon-targeted drug preparation; wherein the mass ratio of ferulic acid to arabinoxylan is 1:10; wherein, based on the mass of arabinoxylan, the amount of pentosanase is 50μg / g arabinoxylan, the amount of glucose is 0.2mg / g arabinoxylan, the amount of peroxidase is 5.5PU / g arabinoxylan, and the amount of glucose oxidase is 5000μg / g arabinoxylan.

[0045] Example 5

[0046] The invention discloses a method for preparing an oral colon-targeted drug preparation, comprising the following steps: dissolving water-soluble arabinoxylan in a phosphate buffer solution (0.01M, pH=6.0) containing bovine serum albumin to obtain an arabinoxylan solution containing bovine serum albumin (wherein the concentration of arabinoxylan is 8wt%), then adding pentosanase, performing enzymolysis reaction at 20°C for 5 minutes, inactivating the enzyme in a boiling water bath after the reaction, sequentially adding glucose, peroxidase and glucose oxidase after cooling, and performing cross-linking reaction at room temperature for 60 minutes to obtain the drug preparation; wherein the mass ratio of bovine serum albumin to arabinoxylan is 1:6; based on the mass of arabinoxylan, the dosage of pentosanase is 40μg / g arabinoxylan, the dosage of glucose is 0.033mg / g arabinoxylan, the dosage of peroxidase is 4.8PU / g arabinoxylan, and the dosage of glucose oxidase is 2000μg / g arabinoxylan.

[0047] Example 6

[0048] The invention discloses a method for preparing an oral colon-targeted drug preparation, comprising the following steps: dissolving water-soluble arabinoxylan in a phosphate buffer solution (0.01M, pH=6.0) containing bovine serum albumin to obtain an arabinoxylan solution containing bovine serum albumin (wherein the concentration of arabinoxylan is 20wt%), then adding pentosanase, performing enzymolysis reaction at 30°C for 2min, inactivating the enzyme in a boiling water bath after the reaction, sequentially adding glucose, peroxidase and glucose oxidase after cooling, stirring at room temperature for cross-linking reaction for 5min, and obtaining the drug preparation; wherein the mass ratio of bovine serum albumin to arabinoxylan is 1:6; based on the mass of arabinoxylan, the dosage of pentosanase is 80μg / g arabinoxylan, the dosage of glucose is 0.33mg / g arabinoxylan, the dosage of peroxidase is 6.0PU / g arabinoxylan, and the dosage of glucose oxidase is 60000μg / g arabinoxylan.

[0049] Example 7

[0050] The invention discloses a method for preparing an oral colon-targeted drug preparation, comprising the following steps: dissolving water-soluble arabinoxylan in a phosphate buffer solution (0.01M, pH=6.0) containing bovine serum albumin to obtain an arabinoxylan solution containing bovine serum albumin (wherein the concentration of arabinoxylan is 10wt%), then adding pentosanase, performing enzymolysis reaction at 25°C for 3min, inactivating the enzyme in a boiling water bath after the reaction, sequentially adding glucose, peroxidase and glucose oxidase after cooling, and performing cross-linking reaction at room temperature for 20min to obtain the drug preparation; wherein the mass ratio of bovine serum albumin to arabinoxylan is 1:6; based on the mass of arabinoxylan, the dosage of pentosanase is 50μg / g arabinoxylan, the dosage of glucose is 0.2mg / g arabinoxylan, the dosage of peroxidase is 5.5PU / g arabinoxylan, and the dosage of glucose oxidase is 5000μg / g arabinoxylan.

[0051] Comparative Example 1

[0052] The only difference between Comparative Example 1 and Example 7 is that the concentration of arabinoxylan in the arabinoxylan solution containing bovine serum albumin is 5 wt %.

[0053] Comparative Example 2

[0054] The difference between Comparative Example 2 and Example 7 is that the concentration of arabinoxylan in the arabinoxylan solution containing bovine serum albumin is 25 wt %.

[0055] Comparative Example 3

[0056] The only difference between Comparative Example 3 and Example 7 is that the amount of pentosanase used is 25 μg / g arabinoxylan.

[0057] Comparative Example 4

[0058] The only difference between Comparative Example 4 and Example 7 is that the amount of pentosanase used is 100 μg / g arabinoxylan.

[0059] Comparative Example 5

[0060] The only difference between Comparative Example 5 and Example 7 is that after the pentosanase was added, the enzymatic reaction was carried out at 15° C. for 1 min.

[0061] Comparative Example 6

[0062] The only difference between Comparative Example 6 and Example 7 is that after the pentosanase was added, the enzymatic reaction was carried out at 30° C. for 10 minutes.

[0063] Test example

[0064] 1. Swelling performance test:

[0065] 1. Preparation of medium:

[0066] Simulated gastric fluid (SGF): Take 23.4 ml of hydrochloric acid and dilute it to 100 ml with water to obtain a dilute hydrochloric acid solution; take 4.1 ml of dilute hydrochloric acid, add about 200 ml of water and 2.5 g of pepsin, shake well, and dilute it to 250 ml with water to obtain SGF.

[0067] Simulated intestinal fluid (SIF) (containing pancreatic enzyme): Take 6.8 g of potassium dihydrogen phosphate, add 500 mL of water to dissolve it, and adjust the pH value to 6.8 with 0.1 mol / L sodium hydroxide; take another 10 g of pancreatic enzyme, add appropriate amount of water to dissolve it, mix the two liquids, and dilute with water to 1000 mL.

[0068] Preparation of simulated colon fluid: take 5.59g of dipotassium hydrogen phosphate, 0.41g of potassium dihydrogen phosphate, and 0.5g of pentosanase, add 1000mL of water to dissolve them.

[0069] 2. Test method:

[0070] 30 mg of the freeze-dried hydrogel of Examples 1-3 was accurately weighed and immersed in each medium. The gel was taken out at 15 min, 30 min, 45 min, 60 min, 120 min, 180 min, 240 min, 300 min, and 360 min after being placed in the beaker. The surface liquid was absorbed with filter paper, and the gel was accurately weighed. The swelling ratio (SR) of the hydrogel at each time point was calculated. The SR calculation formula is as follows:

[0071] SR=(Wt -W0) / W0×100%

[0072] W t represents the mass of hydrogel at time t (g), and W0 represents the dry weight of hydrogel before immersion (g).

[0073] 3. Test results

[0074] The swelling ratios of the hydrogels of Examples 1-3 in various media are shown in Table 1:

[0075] Table 1

[0076]

[0077] As can be seen from Table 1, the hydrogel of the present invention can maintain its cross-linked structure in the environment of the stomach and small intestine, has a very low swelling rate, and can well encapsulate drugs, but is degraded by pentosanase in the colon, the cross-linked structure is destroyed, no longer swells, and its weight is lost instead. This shows that the hydrogel of the present invention can maintain its cross-linked structure in the environment of the stomach and small intestine, the cross-linked structure is degraded and destroyed in the colon, and has good colon targeting performance.

[0078] 2. Drug loading and in vitro release rate test:

[0079] 1. Test method:

[0080] (1) Determination of drug loading:

[0081] 20 mg of the freeze-dried samples of Examples 5-7 and Comparative Examples 1-6 were accurately weighed and placed in a 10 mL volumetric flask, and PBS was added to the scale. The mixture was incubated at 37°C for 2 h, ultrasonicated for 10 min, and the supernatant was taken out. The bovine serum albumin content in the supernatant was determined by the BCA method, and the drug loading (LC) was determined. The formula is:

[0082] LC=(AB) / C×100%

[0083] A is the amount of BSA added, B is the amount of BSA in the supernatant, and C is the total mass of arabinoxylan and BSA.

[0084] (2) In vitro release rate determination:

[0085] 200 mg of samples of Examples 5-7 and Comparative Examples 1-8 were accurately weighed and placed in a dialysis bag with a cutoff of 10000 Da. The dialysis bag was placed in a beaker containing 100 mL of release medium. The speed was 100 rpm / min and stirred in a constant temperature water bath. The temperature was maintained at (37±0.5)°C. First, it was placed in SGF for 2 hours, then taken out and placed in SIF for 4 hours, and then placed in enzyme-added simulated colon fluid for 12 hours. 3 mL of dissolution medium was taken out at 1, 2, 4, 6, 8, 10, 12, and 18 hours, and an equal amount of fresh dissolution medium was added. After the sample was filtered through a 0.45 μm syringe filter, it was analyzed by high performance liquid chromatography to calculate the cumulative release rate.

[0086] 2. Test results:

[0087] The drug loading and in vitro release rate test results of the pharmaceutical preparations of Examples 5-7 and Comparative Examples 1-6 are shown in Table 2:

[0088] Table 2

[0089]

[0090] As can be seen from Table 2, the hydrogel of the present invention has a high drug loading capacity, and its drug release rate in artificial gastric juice and artificial intestinal juice is very low, and its drug release rate in simulated colon fluid is very high, which fully demonstrates that it has excellent colon-targeted drug release performance.

[0091] Therefore, the present invention significantly improves the drug loading capacity and in vitro release rate of the hydrogel by optimizing the dosage of pentosanase, the concentration of arabinoxylan and the reaction conditions, and has good application prospects.

[0092] The above description is only a preferred specific implementation manner of the present invention, but the protection scope of the present invention is not limited thereto. Any technician familiar with the technical field can make equivalent replacements or changes according to the technical scheme and inventive concept of the present invention within the technical scope disclosed by the present invention, which should be covered by the protection scope of the present invention.

Claims

1. A method for preparing a colon-targeted arabinoxylan hydrogel, characterized in that: The following steps are involved: The water-soluble arabinoxylan is dissolved in water to obtain an arabinoxylan solution, and then pentosanase is added to perform enzymolysis reaction at 20-30°C for 2-5 minutes. After the reaction, the enzyme is inactivated in a boiling water bath, and glucose, peroxidase and glucose oxidase are added in sequence after cooling. The mixture is stirred at room temperature for cross-linking reaction to obtain a colon-targeted arabinoxylan hydrogel. In the arabinoxylan solution, the concentration of arabinoxylan is 8-20wt%; based on the mass of arabinoxylan, the amount of pentosanase is 40-80μg / g arabinoxylan; based on the mass of arabinoxylan, the amount of glucose is 0.033-0.33mg / g arabinoxylan, the amount of peroxidase is 4.8-6.0 U / g arabinoxylan, and the amount of glucose oxidase is 2000-60000μg / g arabinoxylan.

2. The method for preparing the colon-targeted arabinoxylan hydrogel according to claim 1, characterized in that: The water-soluble arabinoxylan is prepared by using wheat flour as raw material and adopting an enzymatic hydrolysis-water extraction and alcohol precipitation method.

3. The method for preparing the colon-targeted arabinoxylan hydrogel according to claim 1, characterized in that: The preparation method of the water-soluble arabinoxylan comprises the following steps: uniformly mixing wheat flour and water, stirring at room temperature for a period of time, centrifuging, taking supernatant, concentrating, adding high-temperature α-amylase for enzymatic hydrolysis, then adding glucosidase for enzymatic hydrolysis, cooling, centrifuging, precipitating the obtained supernatant with ethanol to obtain a precipitate, redissolving the precipitate in water, centrifuging, taking supernatant, precipitating with ethanol again, washing the obtained precipitate with anhydrous ethanol, and then freeze-drying to obtain the water-soluble arabinoxylan.

4. The method for preparing the colon-targeted arabinoxylan hydrogel according to claim 3, characterized in that: In the preparation method of the water-soluble arabinoxylan, based on the mass of wheat flour, the dosage of high-temperature α-amylase is 0.3-0.5 kg / t wheat flour, and the temperature of the high-temperature α-amylase enzymatic hydrolysis reaction is 80-95°C; the dosage of glucosidase is 1-2 L / t wheat flour, and the temperature of the glucosidase enzymatic hydrolysis reaction is 55-70°C.

5. The method for preparing the colon-targeted arabinoxylan hydrogel according to claim 1, characterized in that: The cross-linking reaction time is 5-60 minutes.

6. A colon-targeted arabinoxylan hydrogel, characterized in that: Prepared by the preparation method according to any one of claims 1 to 5.

7. Use of the arabinoxylan hydrogel according to claim 6 in preparing a colon-targeted drug carrier.

8. An oral colon-targeted drug preparation, characterized in that: The pharmaceutical preparation comprises an active drug and a drug carrier for encapsulating the active drug, wherein the drug carrier is a colon-targeted arabinoxylan hydrogel prepared by the preparation method according to any one of claims 1 to 5; Alternatively, the pharmaceutical preparation is prepared by replacing the water in the preparation method according to any one of claims 1 to 5 with a buffer solution containing an active drug.

9. The oral colon-targeted drug preparation according to claim 8, characterized in that: The active drug is a polyphenol, polypeptide or protein drug.